Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein

Current Oncology Reports

Volumn 8, Issue 6, 2006, Pages 484-491

  Stemke Hale, Katherine ^b   Hennessy, Bryan ^b   Mills, Gordon B ^b   Mitra, Rahul ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CANCER VACCINE; CHECKPOINT KINASE 2; COLECALCIFEROL DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLITAZONE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NIBRIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; TAMOXIFEN; TISSUE POLYPEPTIDE ANTIGEN; TRANSCRIPTION FACTOR AP 1; TRASTUZUMAB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; EARLY DIAGNOSIS; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA; DNA; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM CIRCULATING CELLS; PATIENT CARE PLANNING; PROGNOSIS; PROTEINS; RNA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33750717187     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0078-5     Document Type: Review

References (68)

1. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study [see comment]. J Natl Cancer Inst 2005, 97:1652-1662.
2. Barrett-Connor EL, Mosca L, et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
3. Gail MH, Costantino JP, Bryant J, et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [see comment] [erratum in J Natl Cancer Inst 2000 Feb 2;92(3):275]. J Natl Cancer Inst 1999, 91:1829-1846.
4. Ozanne EM, Klemp JR, Esserman LJ: Breast cancer risk assessment and prevention: a framework for shared decision-making consultations [see comment]. Breast J 2006, 12:103-113.
5. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al.: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [see comment]. J Clin Oncol 2002, 20:2701-2712.
6. Calderon-Margalit R, Paltiel O: Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004, 112:357-364.
7. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000, 83:1301-1308.
8. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
9. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271.
10. Walsh T, Casadei S, Coats KH, et al.: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388.
11. Dapic V, Carvalho MA, Monteiro ANA: Breast cancer susceptibility and the DNA damage response. Cancer Control 2005, 12:127-136.
12. Thompson D, Easton D: The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004, 9:221-236.
13. Johnson N, Fletcher O, Naceur-Lombardelli C, et al.: Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005, 366:1554-1557.
14. Kammerer U, Thanner F, Kapp M, et al.: Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res 2003, 23:1051-1055.
15. Ellis NA, Kirchhoff T, Mitra N, et al.: Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. Genet Epidemiol 2006, 30:48-61.
16. Meijers-Heijboer H, van Geel B, van Putten WL, et al.: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation [see comment]. N Engl J Med 2001, 345:159-164.
17. Rebbeck TR: Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002, 38(Suppl 6):S15-S17.
18. Balmana J, Sanz J, Bonfill X, et al.: Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 2004, 112:647-652.
19. Paradiso A, Muggia F: Familial breast cancer screening: ethical and social implications [comment]. Ann Oncol 2004, 15(Suppl 1):I5-I6.
20. Moller P: Costs and benefits of diagnosing familial breast cancer [see comment]. Ann Oncol 2004, 15(Suppl 1):I55-I59.
21. Cipollini G, Tommasi S, Paradiso A, et al.: Genetic alterations in hereditary breast cancer [see comment]. Ann Oncol 2004, 15(Suppl 1):I7-I13.
22. Gasco M, Argusti A, Bonanni B, Decensi A: SERMs in chemoprevention of breast cancer. Eur J Cancer 2005, 41:1980-1989.
23. Tibes R, Qiu Y, Lu Y, et al.: Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cell. Mol Cancer Ther 2006, in press.
24. Jager D, Knuth A: Antibodies and vaccines - hope or illusion? Breast 2005, 14:631-635.
25. Sauer G, Kurzeder C, Heilmann V, et al.: Immunotherapy and cancer vaccines in the management of breast cancer [see comment]. Curr Pharm Des 2005, 11:3475-3483.
26. Mittendorf EA, Gurney JM, Storrer CE, et al.: Vaccination with a HER2/ neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery 2006, 139:407-418.
27. Peoples GE, Gurney JM, Hueman MT, et al.: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients [see comment]. J Clin Oncol 2005, 23:7536-7545.
28. Houssami N, Cuzick J, Dixon JM: The prevention, detection, and management of breast cancer. Med J Aust 2006, 184:230-234.
29. Kuhl CK, Kuhn W, Schild H: Management of women at high risk for breast cancer: new imaging beyond mammography. Breast 2005, 14:480-486.
30. Ayers M, Symmans WF, Stec J, et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [see comment]. J Clin Oncol 2004, 22:2284-2293.
31. Chang JC, Wooten EC, Tsimelzon A, et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [see comment]. Lancet 2003, 362:362-369.
32. Iwao-Koizumi K, Matoba R, et al.: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431.
33. Wang Y, Klijn JGM, Zhang Y, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer [see comment]. Lancet 2005, 365:671-679.
34. Callagy G, Pharoah P, Chin S, et al.: Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005, 205:388-396.
35. Rhodes DR, Chinnaiyan AM: Integrative analysis of the cancer transcriptome. Nat Genet 2005, 37(Suppl):S31-37.
36. Rhodes DR, Yu J, Shanker K, et al.: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101:9309-9314.
37. Buckhaults P, Zhang Z, Chen Y-C, et al.: Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003, 63:4144-4149.
38. Linden HM, Stekhova SA, Link JM, et al.: Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006, 24:2793-2799.
39. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [see comment]. N Engl J Med 2005, 353:1673-1684.
40. Rouzier R, Pusztai L, Delaloge S, et al.: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005, 23:8331-8339.
41. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [see comment]. N Engl J Med 2004, 351:2817-2826.
42. van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer [see comment]. Nature 2002, 415:530-536.
43. Jeffrey SS, Lonning PE, Hillner BE: Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Cancer Netw 2005, 3:291-300.
44. Espinosa E, Redondo A, Vara JAF, et al.: High-throughput techniques in breast cancer: a clinical perspective. European J Cancer 2006, 42:598-607.
45. Reis-Filho JS, Milanezi F, Carvalho S, et al.: Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005, 7:R1028-R1035.
46. Cronin M, Pho M, Dutta D, et al.: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42.
47. Paik S, Kim C-y, Song Y-k, Kim W-s: Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2005, 2:246-254.
48. Segal E, Friedman N, Kaminski N, et al.: From signatures to models: understanding cancer using microarrays. Nat Genet 2005, 37(Suppl):S38-S45.
49. Hayes DF: Prognostic and predictive factors revisited. Breast 2005, 14:493-499.
50. Bild AH, Yao G, Chang JT, et al.: Oncogenic pathway signatures in human cancers as a guide to targeted therapies [see comment]. Nature 2006, 439:353-357.
51. Mendrinos S, Nolen JDL, Styblo T, et al.: Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer 2005, 105:178-183.
52. Ricolleau G, Charbonnel C, Lode L, et al.: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 2006, 6:1963-1975.
53. Hudelist G, Singer CF, Pischinger KID, et al.: Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 2006, 6:1989-2002.
54. Dirix L, Van Dam P, Vermeulen P: Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer? Curr Opin Oncol 2005, 17:551-558.
55. Seregni E, Coli A, Mazzucca N, Italian Group Ria-Irma Test IAoNM: Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S15-22.
56. Duffy MJ: Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006, 52:345-351.
57. Cristofanilli M, Hayes DF, Budd GT, et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer [erratum in J Clin Oncol 2005 23:4808]. J Clin Oncol 2005, 23:1420-1430.
58. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer [see comment]. N Engl J Med 2004, 351:781-791.
59. Reinholz MM, Nibbe A, Jonart LM, et al.: Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer [see comment]. Clin Cancer Res 2005, 11:3722-3732.
60. Masuda T-A, Kataoka A, Ohno S, et al.: Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol 2005, 26:721-730.
61. Stathopoulos EN, Sanidas E, Kafousi M, et al.: Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005, 16:240-246.
62. Muller V, Stahmann N, Riethdorf S, et al.: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005, 11:3678-3685.
63. Becker FF, Wang XB, Huang Y, et al.: Separation of human breast cancer cells from blood by differential dielectric affinity. Proc Natl Acad Sci U S A 1995, 92:860-864.
64. Ding C, Chiu RWK, Lau TK, et al.: MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. Proc Natl Acad Sci U S A 2004, 101:10762-10767.
65. Sheen-Chen S-M, Liu Y-W, et al.: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:715-717.
66. Furstenberger G, von Moos R, Lucas R, et al.: Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006, 94:524-531.
67. Rigolin GM, Fraulini C, Ciccone M, et al.: Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531-2535.
68. Houghton J, Stoicov C, Nomura S, et al.: Gastric cancer originating from bone marrow-derived cells [see comment]. Science 2004, 306:1568-1571.